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Abstract 
Background: In addition to conventional chemotherapeutics, nucleic acid-based therapeutics like antisense 
oligodeoxynucleotides (AS-ODN) represent a novel approach for the treatment of bladder cancer (BCa). An efficient 
delivery of AS-ODN to the urothelium and then into cancer cells might be achieved by the local application of multi-
walled carbon nanotubes (MWCNT). In the present study, pristine MWCNT and MWCNT functionalized with hydro-
philic moieties were synthesized and then investigated regarding their physicochemical characteristics, dispersibility, 
biocompatibility, cellular uptake and mucoadhesive properties. Finally, their binding capacity for AS-ODN via hybridi-
zation to carrier strand oligodeoxynucleotides (CS-ODN), which were either non-covalently adsorbed or covalently 
bound to the different MWCNT types, was evaluated.
Results: Pristine MWCNT were successfully functionalized with hydrophilic moieties (MWCNT-OH, -COOH, -NH2, -SH), 
which led to an improved dispersibility and an enhanced dispersion stability. A viability assay revealed that MWCNT-
OH, MWCNT-NH2 and MWCNT-SH were most biocompatible. All MWCNT were internalized by BCa cells, whereupon 
the highest uptake was observed for MWCNT-OH with 40% of the cells showing an engulfment. Furthermore, all 
types of MWCNT could adhere to the urothelium of explanted mouse bladders, but the amount of the covered 
urothelial area was with 2–7% rather low. As indicated by fluorescence measurements, it was possible to attach 
CS-ODN by adsorption and covalent binding to functionalized MWCNT. Adsorption of CS-ODN to pristine MWCNT, 
MWCNT-COOH and MWCNT-NH2 as well as covalent coupling to MWCNT-NH2 and MWCNT-SH resulted in the best 
binding capacity and stability. Subsequently, therapeutic AS-ODN could be hybridized to and reversibly released 
from the CS-ODN coupled via both strategies to the functionalized MWCNT. The release of AS-ODN at experimental 
conditions (80 °C, buffer) was most effective from CS-ODN adsorbed to MWCNT-OH and MWCNT-NH2 as well as from 
CS-ODN covalently attached to MWCNT-COOH, MWCNT-NH2 and MWCNT-SH. Furthermore, we could exemplarily 
demonstrate that AS-ODN could be released following hybridization to CS-ODN adsorbed to MWCNT-OH at physi-
ological settings (37 °C, urine).
Conclusions: In conclusion, functionalized MWCNT might be used as nanotransporters in antisense therapy for the 
local treatment of BCa.
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Background
Bladder cancer (BCa) is the most common malignancy of 
the urogenital system and the ninth most common cancer 
worldwide and thus poses a great challenge to the health 
care sector [1, 2]. BCa treatment depends on tumor stage 
and prognosis of the patient. Superficial, non-muscle-
invasive BCa is initially treated by transurethral resection 
of the bladder tumor followed by a local chemotherapy 
(mitomycin  C, epirubicin, doxorubicin) and/or immu-
notherapy (Bacillus Calmette–Guérin) in order to lower 
the probability of recurrence and progression [1]. This 
adjuvant therapy is directly instilled through a catheter 
into the bladder, which is ideally suitable for such an 
intravesical drug delivery due to its hollow structure [3]. 
Compared to a systemic drug administration, intravesical 
therapy ensures higher drug concentrations at the tumor 
site while minimizing systemic side effects [3].
However, the intravesical drug application has to over-
come some obstacles. The most prominent drawback is 
the low dwell time of the therapeutics due to continuous 
urine production and flushing during voiding. Further-
more, poor adhesion of the drugs to the urothelium and 
deprived penetration into it result in a decreased absorp-
tion and lower effective concentration of the therapeutic. 
Consequently, repeated instillations via catheterizations 
are required, which is inconvenient for the patient and 
may cause inflammatory reactions, bladder irritation 
and infections [3]. Finally, failure of chemotherapy could 
be evoked by the up-regulation of genes associated with 
drug resistance, which in turn provide attractive targets 
for molecular therapy [4, 5]. Complementary to con-
ventional treatment options such as chemotherapy, sur-
gery and radiation, therapeutic nucleic acids including 
antisense oligodeoxynucleotides (AS-ODN) and small 
interfering RNAs (siRNAs) have emerged as a promis-
ing strategy to modify the expression of such tumor-
related genes. In order to achieve an effective therapy, it 
is important to sufficiently deliver the genetic cargo to 
the tumor cells while evading clearance and degradation. 
Consequently, a wide variety of viral and non-viral gene 
therapy vectors have been developed and evaluated in the 
last years.
The development of innovative drug delivery systems 
combining a multifunctional therapy approach is neces-
sary and of utmost interest. Particularly, carbon nano-
tubes (CNT) possess immense potential as nanocarriers 
for such biomedical applications due to their ability to 
be functionalized with various therapeutic agents [6–8]. 
For that matter, we have shown that multi-walled CNT 
(MWCNT) could be loaded with conventional chemo-
therapeutics and thus mediate anti-proliferative effects in 
various cancer cells [9, 10]. The functionalization of CNT 
with AS-ODN or siRNAs represents another promising 
approach to create multifunctional nanocarriers and to 
sufficiently deliver genetic payload to the tumor site [6, 
8]. We and others have previously shown that CNT can 
successfully be coupled with AS-ODN or ODN [11–14]. 
In our prior study, AS-ODN against the angiogenic 
growth factor VEGF were linked via adsorbed carrier 
strand oligodeoxynucleotides (CS-ODN) onto hydroxyl 
group-functionalized MWCNT (MWCNT-OH) [11].
In BCa it is necessary to transport the therapeutic 
agent to the cancer cells located in the bladder urothe-
lium. Therefore, the gene therapy vector has to adhere to 
the bladder urothelium and release its genetic payload. 
Furthermore, it would be advantageous, if the aforemen-
tioned low dwell time of therapeutics inside the bladder 
could be increased. In addition to adhesion to the urothe-
lium, cellular uptake and biocompatibility are important 
prerequisites for the effectiveness of nanocarriers in BCa 
treatment. We have previously demonstrated that vari-
ous types of pristine MWCNT (p-MWCNT) can adhere 
to the urothelium of mouse bladders [15] and can be 
internalized by cancer cells [11, 16]. Another important 
challenge that has to be addressed when using CNT for 
biomedical applications in  vivo is their toxic, inflam-
matory and immunogenic potential. Due to their small 
size and structural resemblance to asbestos, CNT could 
evoke deleterious effects, whereupon MWCNT are gen-
erally less toxic than single-walled CNT (SWCNT) [7]. 
However, by the introduction of functional moieties to 
p-MWCNT their biocompatibility as well as dispersibil-
ity, cellular uptake and mucoadhesive properties might 
be further improved.
In the present study we modified p-MWCNT with dif-
ferent functional groups (MWCNT-OH, -COOH, -NH2, 
-SH) followed by a comprehensive physicochemical 
characterization of the functionalized MWCNT includ-
ing an evaluation of their dispersibility. Furthermore, 
the biocompatibility, cellular uptake and mucoadhesive 
properties of all MWCNT were examined. Then, we 
investigated their binding capacity for CS-ODN by using 
two different attachment strategies: non-covalent adsorp-
tion and covalent binding. Subsequently, the hybridiza-
tion efficiency and the release of AS-ODN coupled to 
MWCNT-bound CS-ODN were evaluated at experimen-
tal and physiological conditions.
Methods
Chemicals
HNO3, NaCl and NaOH were obtained from VWR 
International GmbH (Darmstadt, Germany). 1-Ethyl-
3-(3-dimethylaminopropyl)carbodiimid (EDC), N-hydrox-
ysuccinimid (NHS), 2-(N-morpholino)ethanesulfonic 
acid (MES), tetrahydrofuran (THF) and cysteamine were 
purchased from Sigma-Aldrich (Taufkirchen, Germany). 
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3,4-dihydroxybenzaldehyde (DHBA), N,N-dimethylforma-
mide (DMF),  H2SO4, ethylenediamine, methanol and chlo-
roform were acquired from Merck (Darmstadt, Germany). 
N-(tri(hydroxymethyl)methyl)glycin (tricine) was obtained 
from Alfa Aesar (Karlsruhe, Germany). Disuccinimidyl 
suberate (DSS) and N,N′-dicyclohexylcarbodiimide (DCC) 
were from Thermo Fisher Scientific (Dreieich, Germany) 
and Interchim (Montluçon, France), respectively. The 
buffer ingredients  KH2PO4,  K2HPO4·3  H2O,  Na2HPO4·2 
 H2O,  NaHCO3 and  C2H3NaO2·3  H2O were purchased 
from Gruessing (Filsum, Germany). All buffers were pre-
pared in distilled water and sterilized before use.
Synthesis and characterization of functionalized MWCNT
p-MWCNT were synthesized by chemical vapor depo-
sition as described previously [15, 17]. The catalyst par-
ticles were removed by washing with 32.5% nitric acid, 
which also leads to some oxidation of the p-MWCNT. 
Following purification p-MWCNT were filtered, washed 
with deionized water and dried at 110  °C for several 
hours [17]. They are composed of individual filaments 
of graphene walls with an average outer diameter and 
length of 11 and 980  nm, respectively [15]. To generate 
MWCNT-OH, hydroxyl groups were attached to the sur-
face by 1,3-dipolar cycloaddition with tricine and DHBA 
as reactants (Fig.  1) [11]. For synthesis of MWCNT-
COOH (Fig.  1), 200  mg p-MWCNT were dispersed in 
 H2SO4/HNO3 (3:1) for 3 h in a sonication bath, filtrated 
and washed with distilled  H2O until the pH was neu-
tral. The product MWCNT-COOH was dried overnight 
at 108  °C. Synthesis of MWCNT-NH2 and MWCNT-
SH was performed as described by Jeong et  al. with 
an extended reaction time (Fig.  1) [18]. Briefly, 10  mg 
MWCNT-COOH and 10  mg DCC were sonicated for 
5 min in 2 ml THF and stirred for 30 min. The dispersion 
was filtrated and washed with THF and methanol. There-
after, the activated MWCNT were dispersed in THF. To 
produce MWCNT-NH2 and MWCNT-SH 4 ml ethylene-
diamine in 2 ml THF and 25 mg cysteamine in 4 ml THF, 
respectively, were added and the mixtures were stirred 
for 2.5 h. Afterwards, the dispersions were filtrated and 
washed with THF. The final products were dried for 72 h 
at 40 °C.
Finally, pristine and functionalized MWCNT were 
analyzed by X-ray photoelectron spectroscopy (XPS), 
thermogravimetric analysis (TGA), Fourier transform 
DMF
130 °C, 96 h
p-MWCNT
MWCNT-COOH
MWCNT-OH
MWCNT-NH2
MWCNT-SH
DCC, THF
RT, 3 h
H2SO4/HNO3
RT, 3 h
tricine DHBA
ethylenediamine
cysteamine
H
Fig. 1 Scheme for the preparation of functionalized MWCNT from pristine MWCNT. DCC: N,N′-dicyclohexylcarbodiimide; DHBA: 3,4-dihydroxyben-
zaldehyde; DMF: N,N-dimethylformamide; RT: room temperature; THF: tetrahydrofuran
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infrared spectroscopy (FT-IR) and Raman spectroscopy 
as described previously [11, 15]. XPS experiments were 
carried out in an ultrahigh vacuum system equipped 
with the hemispherical electron analyzer PHOIBOS 100 
(SPECS, Berlin, Germany) operating at constant pass 
energy (15  eV). The photoelectrons were excited with 
non-monochromatic Mg  Kα (1253.6  eV) radiation. The 
X-ray source was run at a power of 300 W. The powder 
materials were fixed in special sample holders with molds 
of 4 mm diameter. The analysis region was approximately 
1  mm in diameter and the resolution was 0.2  eV. TGA 
was carried out in a SDT Q600 (TA Instruments, Esch-
born, Germany) with a heating rate of 10  K/min and a 
synthetic air flow of 100  ml/min. FT-IR spectra were 
recorded at room temperature in transmission mode with 
an IFS 113v spectrometer (Bruker, Karlsruhe, Germany) 
with a resolution of 0.5  cm−1. The Raman spectroscopy 
measurements were performed using a Raman–Fourier-
transform-spectrometer DXR SmartRaman (Thermo 
Fisher Scientific) at a wavelength of 532 nm and a laser 
power of 8 mW. The resolution was 1 cm−1.
Stock dispersions of the MWCNT (1 mg/ml) in phos-
phate buffered saline (PBS; pH 7.4) were prepared by 
sonication for 30 min in an ultrasonic bath. To compare 
the dispersion stability of the pristine and functionalized 
MWCNT, dispersions with a MWCNT concentration 
of 1 mg/ml were stored at room temperature for 24 h or 
three months. MWCNT dilutions for the cellular assays 
were prepared from the stock dispersions using cell cul-
ture medium.
Cell culture, MWCNT treatment and cell viability assay
The human BCa cell line EJ28 (University of Frankfurt, 
Frankfurt, Germany) was cultured in Dulbecco’s modified 
eagle’s medium (DMEM; 4.5  g/l glucose) with 10% fetal 
calf serum, 1% gentamicin and 1% non-essential amino 
acids (all from GE Healthcare, Munich, Germany) in a 
humidified atmosphere containing 5%  CO2 at 37 °C. After 
seeding 300 cells per well in 96well plates and adherence 
for 72 h, cells were treated with 0.1 mg/ml MWCNT dis-
persions in DMEM. 24 h after treatment the medium was 
changed. Cell viability was examined in quadruplicates 
48, 72 and 96 h after MWCNT treatment start using the 
cell proliferation reagent WST-1 (Roche, Mannheim, Ger-
many) according to the manufacturer’s protocol.
Transmission electron microscopy of MWCNT uptake 
into cells
The cellular uptake of MWCNT was investigated 
by transmission electron microscopy (TEM) stud-
ies. 100,000 EJ28 cells were seeded in 25  cm2-flasks. 
After 72  h adherent cells were treated with 0.1  mg/ml 
MWCNT. Cells without MWCNT treatment served as 
control. After 24  h incubation cells were harvested by 
trypsin/EDTA treatment. TEM samples were prepared 
by the Institute of Pathology (TU Dresden, Dresden, 
Germany) as described previously and examined with an 
EM900 transmission electron microscope (Zeiss, Jena, 
Germany) [11]. Then, the localization of the MWCNT 
inside the cells was determined and the amount of cells 
showing a cellular uptake was estimated.
Mucoadhesion studies
Mucoadhesive properties of the different functional-
ized MWCNT were evaluated as described previously 
[15]. Briefly, explanted mouse bladders (animal facility, 
Medical Faculty, TU Dresden, Dresden, Germany) were 
incubated with the various MWCNT types (0.2  mg/ml) 
for 1  h at room temperature using Franz diffusion cells 
(GauerGlas, Püttlingen, Germany). Subsequently, tissue 
sections were prepared from formalin-fixed paraffin-
embedded tissues, stained with hematoxylin–eosin (HE) 
and evaluated by light microscopy. Percentage of urothe-
lial area covered by MWCNT was considered in relation 
to total urothelial area by using the software ImageJ (Ver-
sion 1.4.3.67, Broken Symmetry Software).
Binding of CS‑ODN to MWCNT and AS‑ODN hybridization
CS-ODN, AS-ODN and non-complementary nonsense 
ODN (NS-ODN) as well as amino-group modified CS-
ODN  (NH2-CS-ODN) and maleimide-functionalized 
CS-ODN (Mal-CS-ODN) were purchased from biomers.
net (Ulm, Germany); the respective sequences are listed 
in Table  1. The selected AS-ODN were targeted at the 
angiogenic growth factor VEGF [19] and CS-ODN repre-
sent the appropriate complementary sequence to the AS-
ODN. The sequence of the NS-ODN was designed in that 
way that there is no binding to the CS-ODN, which was 
verified by using the software mfold 2.3 (http://unafold.
rna.albany.edu/?q=mfold).
In order to covalently bind CS-ODN to the modi-
fied MWCNT, specific activation procedures which are 
frequently used for the respective modifications of the 
MWCNT had to be conducted (Table 1). In the following 
procedures, the concentration of sodium chloride and the 
ionic strength of the buffer solutions were kept constant 
in order to have the same ionic conditions in all buffer sys-
tems. Furthermore, 1 mg MWCNT was firstly dispersed 
in 1 ml PBS (pH 7.4) for 30 min in an ultrasonic bath and 
then the respective amount of MWCNT was used for the 
binding of CS-ODN.
Adsorption of CS‑ODN to pristine and modified MWCNT
0.5 nmol CS-ODN were mixed with 50 µg MWCNT in 
0.5 ml PBS and then shaken at room temperature over-
night. Afterwards, the excess of CS-ODN was removed 
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by centrifugation over a centrifugal filter (with modified 
nylon, pore size 0.2 µm; VWR International GmbH) for 
1  min at 2300  rcf followed by two washing steps with 
0.5 ml PBS.
EDC/NHS‑activation of MWCNT‑COOH and coupling 
with  NH2‑CS‑ODN
50  µg MWCNT-COOH were activated with 100  mM 
EDC and 100 mM NHS in 0.5 ml MES (pH 6.0, 100 mM) 
by shaking the mixture for 1  h at room temperature. 
The buffer was removed by separation of the MWCNT-
COOH via centrifugation over a centrifugal filter for 
1  min at 2300  rcf. Afterwards, the activated MWCNT-
COOH were mixed with 0.5  nmol  NH2-CS-ODN in 
0.5 ml potassium phosphate buffer (pH 8.0) and shaken 
at room temperature overnight followed by the removal 
of the excess CS-ODN.
Coupling of DSS‑activated  NH2‑CS‑ODN to MWCNT‑NH2
25  µl of a 1  mM  NH2-CS-ODN solution in water was 
mixed with 7.5 µl  NaHCO3-buffer (pH 8.6, 1 M) and 25 µl 
DSS (10  mg/ml in DMSO). Excess DSS was separated 
using an illustra™ NAP™-10 sephadex™ G-25 column 
(GE Healthcare, Munich, Germany) and activated ODN 
were concentrated by  Amicon® Ultra centrifugal filters 
(3000 MWCO; Merck, Darmstadt, Germany). 0.5  nmol 
of the activated  NH2-CS-ODN were mixed with 50  µg 
MWCNT-NH2 in 0.5  ml PBS and shaken at room tem-
perature overnight followed by the removal of the excess 
CS-ODN.
Coupling of Mal‑CS‑ODN to MWCNT‑SH
0.5 nmol Mal-CS-ODN were mixed with 50 µg MWCNT-
SH in 0.5 ml PBS and shaken at room temperature over-
night followed by the removal of the excess CS-ODN.
AS‑ODN hybridization
AS-ODN or NS-ODN (0.1  nmol in 200  µl PBS) were 
added onto the centrifugal filters containing 50  µg 
MWCNT and allowed to hybridize for 30 min. The excess 
of AS-ODN or NS-ODN from the ODN-MWCNT-mix-
tures was removed by centrifugation over a centrifugal 
filter for 1 min at 2300 rcf followed by two washing steps 
with 0.5 ml PBS.
The aforementioned procedures resulted in the fol-
lowing maximum concentrations of ODN per mg CNT: 
10 nmol/mgCNT for CS-ODN and 2 nmol/mgCNT for AS-
ODN and NS-ODN.
Fluorescence measurements for binding and release 
studies
For binding and release studies with the subsequent fluo-
rescence measurements the respective CS-ODN were 
labeled at the 3′-end, whereas AS-ODN and NS-ODN 
were labeled at the 5′-end with 6-carboxyfluorescein 
(6-FAM) for release in PBS or Dy-557 for release in NaCl 
and urine. Following binding of the CS-ODN to the vari-
ous MWCNT the supernatant and the two washing solu-
tions were used for fluorescent measurements. For the 
release experiments at experimental conditions, 0.5  ml 
PBS was given to the various MWCNT with attached 
ODN on the centrifugal filter. The release was carried out 
at 80  °C for 10  min (1. release) and for another 10  min 
(2. release). The release at physiological conditions was 
carried out in 0.9% NaCl solution and pure urine as well 
as mixtures thereof at 37  °C for 1  h (1. release) and for 
24  h (2. release). Afterwards, the solutions were centri-
fuged through the centrifugal filter again to remove the 
released ODN. The fluorescent measurements of the 
supernatant, the washing solutions and the release solu-
tions were performed in a precision cuvette made from 
quartz glass  Suprasil® (Hellma GmbH & Co. KG, Müll-
heim, Germany) with the F-4500 FL spectrophotometer 
from Hitachi (Tokio, Japan) with time scan mode for 60 s. 
The excitation and emission wavelengths for 6-FAM were 
λ =  494 and λ =  515  nm, respectively. For Dy-557 the 
excitation wavelength was λ = 555 nm and the emission 
wavelength was λ = 576 nm.
Table 1 Sequences and intended use of synthetic oligodeoxynucleotides
AS-ODN antisense oligodeoxynucleotides, CS-ODN carrier strand oligodeoxynucleotides, Mal maleimide, Mal-CS-ODN maleimide-functionalized CS-ODN, NH2-CS-ODN 
amino-group modified CS-ODN, NS-ODN nonsense oligodeoxynucleotides
Type Sequence Intended use and remarks
CS-ODN 5′-ACG CTG CCG CCA CCA CAC CA-3′ Adsorbed to pristine and modified MWCNT
NH2-CS-ODN 5′-NH2-C6-ACG CTG CCG CCA CCA CAC CA-3′ Covalently bound to EDC/NHS-activated MWCNT-COOH; following activation with DSS 
covalently bound to MWCNT-NH2
Mal-CS-ODN 5′-Mal-ACG CTG CCG CCA CCA CAC CA-3′ Covalently bound to MWCNT-SH
AS-ODN 5′-TGG TGT GGT GGC GGC AGC GT-3′ Therapeutic AS-ODN against the angiogenic growth factor VEGF, complementary to 
CS-ODN
NS-ODN 5′-CCA AAC CCG TCA ATC AAG TC-3′ Control, non-complementary to CS-ODN
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Statistical analyses
All experiments were reproduced independently at least 
twice. Data are presented as mean  ±  standard devia-
tion, if not otherwise indicated. Outliers were identi-
fied by using the Dixon test and were not considered for 
averaging.
Results
Characterization of pristine and functionalized MWCNT
XPS spectra of all samples were measured and the ele-
mental distribution was calculated (Table 2). p-MWCNT 
did not contain any nitrogen and sulfur. Due to the wash-
ing procedure of the sample with nitric acid to remove 
catalyst particles and amorphous carbon, the p-MWCNT 
were slightly oxidized resulting in an oxygen content of 
1.8%. Compared to p-MWCNT, MWCNT-OH showed 
an increased content of oxygen (7.3%) and nitrogen 
(3.2%) based on the additional 1,3-dipolar cycloaddition. 
The sonication in nitric and sulfuric acid increased the 
oxygen content up to 12.4% for MWCNT-COOH and 
incorporated also some nitrogen into the sample (0.4%). 
This acid treatment formed different oxygen-containing 
functional groups on the surface of the MWCNT-COOH 
such as hydroxyl and aldehyde groups, but mainly car-
boxyl groups. The amidation of MWCNT-COOH with 
ethylenediamine resulted in MWCNT-NH2 with an 
increased nitrogen content (4.1%) combined with a 
decreased oxygen content (8.5%), because OH-groups 
were exchanged for NH-CH2-CH2-NH2 substituents. 
MWCNT-SH behaved similar to MWCNT-NH2. The 
sulfur content of 1.3% indicated a successful reaction.
The highest overall functionalization degrees were 
detected for MWCNT-OH (4.4  nmol/mgCNT) and 
MWCNT-COOH (4.9  nmol/mgCNT) (Table  2). In 
MWCNT-OH five hydroxyl groups were added simulta-
neously and thus contributed to the high functionalization 
degree. The functionalization values for MWCNT-NH2 
(1.5  nmol/mgCNT) and MWCNT-SH (1.0  nmol/mgCNT) 
were lower indicating that not all carboxyl groups had 
been substituted. Furthermore, cysteamine had only one 
amino group to react with the activated carboxyl group, 
whereas ethylenediamine had two. This could contribute 
to the even lower functionalization degree of MWCNT-
SH compared to MWCNT-NH2.
TGA measurements (Additional file  1: Figure S1A) 
showed that p-MWCNT were stable until a tempera-
ture of 550 °C and then started to decompose completely 
to  CO2 within a temperature range of 550–650  °C. In 
contrast, the thermal stability of MWCNT-COOH, 
MWCNT-NH2 and MWCNT-SH was given until a tem-
perature of 150  °C and between 150 and 250  °C they 
started to oxidize slowly. MWCNT-OH were stable until 
250  °C and then slowly oxidized in a temperature range 
of 250–320  °C. This much lower thermal stability of all 
functionalized MWCNT can be attributed to the more 
unstable functional groups on their surface. Pristine and 
functionalized MWCNT started to decompose quickly 
at 550–650 °C. For MWCNT-NH2 and MWCNT-SH the 
weight loss before degradation of the MWCNT back-
bone was higher than for MWCNT-COOH due to the 
attached groups on the surface of MWCNT-NH2 and 
MWCNT-SH, which oxidize at lower temperatures.
The FT-IR spectra (Additional file 1: Figure S1B) of all 
MWCNT showed bands at 3435, 1634 and 1384  cm−1 
corresponding to O–H, C=O and C–O bonds, respec-
tively. In addition, MWCNT-NH2 and MWCNT-SH 
exhibited another C=O stretching vibration (amide 
group) at 1580  cm−1, which confirmed the successful 
amidation with ethylenediamine or cysteamine of these 
samples.
The Raman spectra (Additional file  1: Figure S1C) 
showed for all samples the two standard peaks at 
1350  cm−1 (G-band) and 1591  cm−1 (D-band), which 
corresponded to graphitic and non-graphitic carbon, 
respectively. The ratio between the G-band and the 
D-band did not change during the functionalization pro-
cesses. Raman spectroscopy was not sensitive enough to 
visualize the differences in the samples.
In order to examine the dispersibility of the MWCNT 
and the long-term behavior of their dispersions, 
MWCNT in PBS were sonicated followed by a monitor-
ing of the dispersions. Homogenous dispersions were 
only obtained for the functionalized MWCNT (Addi-
tional file  1: Figure S2). In contrast, p-MWCNT could 
Table 2 Results of XPS measurements of pristine and functionalized MWCNT
Sample C 1s [%] N 1s [%] O 1s [%] S 2s [%] Functionalization degree 
[nmol/mgCNT]
p-MWCNT 98.2 0.0 1.8 0.0 –
MWCNT-OH 89.5 3.2 7.3 0.0 4.4
MWCNT-COOH 86.1 0.4 12.4 0.0 4.9
MWCNT-NH2 87.4 4.1 8.5 0.0 1.5
MWCNT-SH 89.4 2.3 7.0 1.3 1.0
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not be dispersed sufficiently in PBS and consequently 
coarse agglomerates were observed. 24  h after sonica-
tion, sedimentation of all dispersions was detected with 
p-MWCNT showing the highest sedimentation rate. The 
functionalized MWCNT could easily be converted back 
into dispersion by soft agitation of the sample vessel. 
After incubation for three months, all samples showed 
the same sedimentation behavior as observed at the 24 h 
time point.
Impact of pristine and functionalized MWCNT on the cell 
viability of EJ28 BCa cells
Next, the impact of 0.1 mg/ml pristine and functionalized 
MWCNT on cellular viability was tested in EJ28 BCa 
cells. 48  h after treatment start, all MWCNT modifica-
tions caused a considerable inhibition of cellular viability 
(Fig.  2), whereupon MWCNT-COOH and p-MWCNT 
caused the strongest reduction of the relative cell viability 
down to about 40%. In contrast, the relative cell viabil-
ity following treatment with MWCNT-OH, MWCNT-
NH2 and MWCNT-SH was approximately 60% after 
48  h. However, the relative cell viability increased over 
the investigated time period resulting in the lowest inhi-
bition for all MWCNT modifications 96  h after treat-
ment start. At this time point, the relative cell viability 
was 60% for MWCNT-COOH, 75% for p-MWCNT and 
between 82 and 94% for MWCNT-OH, MWCNT-NH2 
and MWCNT-SH. The detrimental impact of the various 
MWCNT on the cell viability was as follows: MWCNT-
COOH > p-MWCNT > MWCTNs-OH/MWCNT-NH2/
MWCNT-SH.
Cellular uptake of pristine and functionalized MWCNT
Additionally, the cellular uptake of MWCNT was inves-
tigated with TEM analysis (Fig.  3). The vacuoles of 
untreated cells were significantly smaller than the vacu-
oles of treated cells. The MWCNT taken up by the cells 
could be mostly found as agglomerates in the vacuoles. 
No MWCNT were located in the cell nuclei. After treat-
ment with p-MWCNT 5–10% of cells showed an uptake, 
whereas for MWCNT-COOH and MWCNT-NH2 
30–35% of cells exhibited a MWCNT uptake. MWCNT-
SH showed the lowest uptake with 5% of cells having 
MWCNT-SH inside their vacuoles. After treatment with 
MWCNT-OH, 40% of cells showed an uptake, where-
upon 90% of the incorporated MWCNT-OH could be 
found in vacuoles and 10% were included directly in the 
cytoplasm of cells. MWCNT-OH in the cytoplasm were 
individualized and not agglomerated like in the vacuoles 
(Additional file 1: Figure S3).
Mucoadhesive potential of pristine and functionalized 
MWCNT
Next, ex vivo mucoadhesion experiments of the pristine 
and modified MWCNT were performed on explanted 
mouse bladders. All MWCNT types displayed only an 
adhesion to the urothelium and did not penetrate into 
deeper tissue layers. Furthermore, the surface of the 
mouse bladders showed no visible signs of damage fol-
lowing incubation with MWCNT. The mean percentages 
of MWCNT-covered surface areas along the urothelium 
were estimated to evaluate the mucoadhesive proper-
ties of the different modified MWCNT types (Fig.  4) 
and ranged from 2.3% for MWCNT-OH to 5.9% for 
MWCNT-COOH. The unmodified p-MWCNT showed 
a slightly higher mean percentage (6.7%) of covered sur-
face area of the urothelium than the modified MWCNT.
Binding of CS‑ODN to MWCNT
In the present study, two different strategies were 
employed in order to attach CS-ODN to the MWCNT: 
via non-covalent adsorption and covalent binding. 
Because a fluorescence quenching occurred when meas-
uring fluorescent-labeled CS-ODN directly on the sur-
face of MWCNT, the amount of CS-ODN coupled to 
MWCNT could only be measured indirectly. By meas-
uring the amount of CS-ODN in the supernatant of the 
binding reaction and in the washing solutions an estima-
tion of coupled CS-ODN to the surface of MWCNT was 
possible. A high concentration of CS-ODN in these solu-
tions would indicate a poor attachment to the MWCNT. 
Furthermore, a release study was performed at 80  °C, 
because it has been shown that non-covalent interac-
tions are not stable at higher temperatures resulting in a 
release of the CS-ODN [20].
Fig. 2 Time-dependent influence of pristine and functionalized 
MWCNT on the relative cell viability of EJ28 cells. Cells were treated 
for 24 h with 0.1 mg/ml MWCNT and then cellular viability was meas-
ured 48, 72 and 96 h after treatment start by using the WST-1 assay. 
Untreated cells served as control (100%)
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Fig. 3 Internalization of pristine and functionalized MWCNT by EJ28 cells as visualized by TEM. Representative TEM images of EJ28 cells after incu-
bation with 0.1 mg/ml MWCNT for 24 h are depicted. Cells without MWCNT treatment served as control. Black arrows indicate MWCNT inside the 
cells. Cy: cytoplasm; Ly: lysosome; M: mitochondrion; Nu: nucleus
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0
2
4
6
8
10
co
ve
re
d 
ar
ea
 [%
]
Fig. 4 Mean percentage of urothelial area covered by pristine or functionalized MWCNT. Explanted mouse bladders were incubated with the vari-
ous MWCNT types (0.2 mg/ml) for 1 h at room temperature using Franz diffusion cells. Subsequently, the coverage of urothelium by MWCNT was 
evaluated on HE-stained tissue sections by light microscopy. Results are depicted as mean ± standard error
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First, the non-covalent adsorption of CS-ODN to pris-
tine and modified MWCNT was investigated (Fig.  5a). 
The lowest amount of CS-ODN in the supernatant 
was achieved for p-MWCNT with 0.30  nmol/mgCNT. 
Additionally, there were no CS-ODN in the wash-
ing and releasing solutions. Altogether, this indicates 
a good adsorption capacity and stability for CS-ODN 
to p-MWCNT. The highest amount of CS-ODN in 
the supernatant was measured for MWCNT-OH with 
7.60  nmol/mgCNT followed by 7.20  nmol/mgCNT in the 
supernatant after CS-ODN-adsorption to MWCNT-
SH. Additionally, there was a rather high release at 80 °C 
for these MWCNT modifications. Therefore, the major 
part of the initially added CS-ODN (10  nmol/mgCNT) 
was not coupled to the surface of MWCNT-OH and 
MWCNT-SH. For MWCNT-NH2 and MWCNT-COOH 
the CS-ODN concentration in the supernatant was 
2.30 and 1.70  nmol/mgCNT, respectively. The amount of 
CS-ODN in the washing and release solutions was also 
lower compared to MWCNT-OH and MWCNT-SH. 
The adsorption capacity and stability of CS-ODN to 
MWCNT reflected by a decreasing amount CS-ODN in 
the supernatant, washing and releasing solutions were 
as follows: p-MWCNT > MWCNT-COOH > MWCNT-
NH2 > MWCNT-SH > MWCNT-OH.
Next, functionalized MWCNT were used for the cova-
lent coupling of fluorescent-labeled CS-ODN. First, the 
carboxyl-groups of MWCNT-COOH were activated 
by EDC/NHS-treatment, so that they then could react 
with the amino-groups of amino-group-modified CS-
ODN  (NH2-CS-ODN). The amount of  NH2-CS-ODN 
in the supernatant after EDC/NHS-activation and in 
the first release solution was about 2.60 and 0.30 nmol/
mgCNT, respectively, indicating a moderate to good 
binding capacity and stability (Fig. 5b). Surprisingly, the 
amount of  NH2-CS-ODN in the supernatant and after 
the release was nearly zero for  NH2-CS-ODN coupled to 
MWCNT-COOH without EDC/NHS-activation reflect-
ing a better binding capacity and stability than with EDC/
NHS-activation.
NH2-CS-ODN were activated by DSS and used for 
a covalent binding to the amino-groups of MWCNT-
NH2. In comparison to the non-covalent binding of 
 NH2-CS-ODN without DSS-activation to MWCNT-
NH2, the amount of  NH2-CS-ODN in the superna-
tant and after release for DSS-activated  NH2-CS-ODN 
to MWCNT-NH2 was much lower (Fig.  5b): 0.07 
vs 1.60  nmol/mgCNT and 0.07 vs 0.30  nmol/mgCNT, 
respectively. This indicates a specific binding reaction 
and strength for the DSS-activated  NH2-CS-ODN to 
MWCNT-NH2.
For maleimide-functionalized CS-ODN (Mal-CS-
ODN), which react with thiol groups of MWCNT-SH, 
the situation was similar (Fig. 5b). The direct comparison 
Fig. 5 Release of CS-ODN attached to pristine or functionalized MWCNT. Depicted is the amount of released CS-ODN following a adsorption or 
b covalent binding with and without prior activation to pristine or modified MWCNT. The initial concentration of the 6-FAM-labeled CS-ODN was 
10 nmol/mgCNT and the released amount was determined by fluorescence measurements in the supernatant of the binding reaction, in the wash-
ing solution (twice with PBS) and in the release solution (in PBS at 80 °C for 2 × 10 min). The specific activation procedures prior to the covalent 
binding were as follows:  NH2-CS-ODN coupled to MWCNT-COOH activated with EDC/NHS, DSS-activated  NH2-CS-ODN coupled to MWCNT-NH2, 
maleimide-activated CS-ODN coupled to MWCNT-SH. Control experiments were performed without specific activation
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of Mal-CS-ODN coupled to MWCNT-SH and CS-
ODN without maleimide-functionalization adsorbed to 
MWCNT-SH showed a CS-ODN concentration of 0.30 
and 1.90 nmol/mgCNT, respectively, in the supernatants. 
Also, the CS-ODN amount in the releasing solutions was 
lower for Mal-CS-ODN coupled to MWCNT-SH com-
pared to CS-ODN without maleimide-functionalization. 
This demonstrates that Mal-CS-ODN could be covalently 
and specifically coupled to MWCNT-SH resulting in a 
good binding stability.
The binding capacity and stability of CS-ODN to the 
modified MWCNT after specific activation were as fol-
lows: MWCNT-NH2 > MWCNT-SH > MWCNT-COOH.
Hybridization of AS‑ODN to CS‑ODN‑MWCNT and release 
at experimental conditions
After adsorption or covalent coupling of CS-ODN to 
MWCNT, the complementary AS-ODN could hybridize 
to them. Non-complementary NS-ODN served as con-
trol to show the specificity of the AS-ODN-hybridization 
to the CS-ODN. Afterwards, the release of AS-ODN 
and NS-ODN was performed at 80  °C, which is above 
the melting temperature of AS-ODN and NS-ODN 
ensuring a high release rate. Regardless of the attach-
ment method of the CS-ODN to the MWCNT, most of 
the AS-ODN were already released after 10 min at 80 °C 
in PBS (1. release) and only small amounts of AS-ODN 
were released after additional 10 min (2. release; Fig. 6). 
The first release of AS-ODN from CS-ODN which 
were adsorbed to MWCNT was highest for MWCNT-
NH2 (0.20  nmol/mgCNT) followed by MWCNT-OH 
(0.16  nmol/mgCNT), MWCNT-SH (0.11  nmol/mgCNT) 
and MWCNT-COOH (0.09  nmol/mgCNT) (Fig. 6a). The 
lowest release of AS-ODN with 0.05  nmol/mgCNT was 
achieved for p-MWCNT (Fig. 6a), although they had the 
highest amount of adsorbed CS-ODN as aforementioned. 
The release of AS-ODN from CS-ODN covalently bound 
to MWCNT-COOH (0.26 nmol/mgCNT), MWCNT-NH2 
(0.25 nmol/mgCNT) or MWCNT-SH (0.34 nmol/mgCNT) 
were similar amongst these MWCNT with MWCNT-
SH showing a slightly higher release rate (Fig. 6b). For all 
samples the release of NS-ODN was clearly lower than 
for AS-ODN indicating the specific hybridization of AS-
ODN to the CS-ODN at the MWCNT surface (Fig. 6).
While comparing the release of NS-ODN, which can 
only adsorb to the MWCNT, with the amount of released 
AS-ODN it is possible to estimate the ratio of unspecific 
adsorption for AS-ODN. The difference between the 
release of NS-ODN and AS-ODN, which corresponds 
to the hybridization rate of AS-ODN, was highest for 
MWCNT-OH. In detail, eight times more AS-ODN than 
NS-ODN were released from MWCNT-OH, which cor-
responds to a adsorption rate of AS-ODN to MWCNT-
OH of 12.5% compared to NS-ODN with an estimated 
adsorption rate of 100%. The estimated adsorption rate 
of AS-ODN was 20% for MWCNT-NH2 and 33% for 
Fig. 6 Release of AS-ODN or NS-ODN following hybridization to CS-ODN attached to pristine or functionalized MWCNT. Depicted is the amount 
of released AS-ODN or NS-ODN following hybridization to a adsorbed or b covalently bound CS-ODN to pristine or modified MWCNT. The initial 
concentration of the 6-FAM-labeled AS-ODN and NS-ODN was 2 nmol/mgCNT and the released amount was determined by fluorescence meas-
urements in the release solution (in PBS at 80 °C for 2 × 10 min). The specific activation procedures prior to the covalent binding were performed 
analog to Fig. 2. Non-complementary NS-ODN served as control
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p-MWCNT, MWCNT-COOH and MWCNT-SH. Con-
sequently, CS-ODN adsorbed to MWCNT-OH and 
MWCNT-NH2 had the highest hybridization rate of 
AS-ODN.
Release of AS‑ODN at physiological conditions in urine
For prospective medical applications MWCNT carry-
ing therapeutic AS-ODN should be instilled into the 
urinary bladder in a physiological NaCl solution (0.9%). 
Therefore and exemplarily, the release of AS-ODN after 
hybridization to CS-ODN adsorbed to MWCNT-OH 
was investigated at 37  °C using 0.9% NaCl solution and 
pure urine as well as mixtures thereof (Fig. 7). The release 
of AS-ODN was lowest in the 0.9% NaCl solution and 
increased with an increasing portion of urine in the mix-
ture. Accordingly, the release of AS-ODN was the highest 
in pure urine: 0.19 nmol/mgCNT after 1 h and 0.20 nmol/
mgCNT after 24 h.
Discussion
CNT may represent a viable option as gene therapy 
vectors, because they can be chemically tailored at the 
surface in order to improve drug binding, dispersibil-
ity, biocompatibility and/or targeting [6]. Furthermore, 
CNT are known to penetrate cell membranes and thus 
could unload their cargo intracellularly [6, 8]. Because 
p-MWCNT are usually difficult to disperse in aque-
ous solutions, various types of surface functionaliza-
tion with hydrophilic moieties are employed not only 
to increase their dispersibility, but also to improve their 
biocompatibility. In the present study, p-MWCNT were 
functionalized with hydroxyl groups (MWCNT-OH) 
via 1,3-dipolar cycloaddition of tricine/DHBA and with 
carboxylic groups (MWCNT-COOH) by oxidation with 
nitric and sulfuric acid. The amino groups (MWCNT-
NH2) were introduced by the formation of an amide 
bond between ethylene diamine and carboxylic groups of 
MWCNT-COOH, whereas cysteamine was used instead 
of ethylene diamine for the attachment of thiol groups 
(MWCNT-SH). Depending on the moiety the degree 
of functionalization ranged between 1.0 and 4.9  nmol/
mgCNT. By increasing the functionalization degree the 
MWCNT showed a much lower thermal stability due 
to the more unstable functional groups on their surface. 
MWCNT-NH2 and MWCNT-SH started to decom-
pose at lower temperatures in comparison to all other 
functionalized MWCNT, because the oxidation of these 
functional groups occurred at lower temperatures. Fur-
thermore, the ratio between the G-band and the D-band 
did not change during the functionalization processes 
indicating that no further defects were introduced into 
the modified MWCNT.
The prerequisite for the biomedical application of 
MWCNT is the formation of stable dispersions with-
out agglomerates or aggregates. Therefore, an initial 
assessment of the dispersibility and the long-term dis-
persion stability of the different MWCNT modifica-
tions was performed. The introduction of hydrophilic 
moieties to the MWCNT surface led to a superior dis-
persibility and enhanced dispersion stability compared 
to unmodified p-MWCNT. Notably, the functional-
ized MWCNT formed good dispersions in PBS with-
out the help of known adjuvants such as serum albumin 
and polyethylene glycol [21]. In the present study, the 
MWCNT modifications MWCNT-OH, MWCNT-NH2 
and MWCNT-SH exhibited a lower impact on the cel-
lular viability of EJ28 BCa cells than oxidized MWCNT-
COOH and unmodified p-MWCNT. Due to their 
hydrophobic surface, p-MWCNT are poorly dispers-
ible in aqueous solutions and tend to agglomerate and 
thus induce higher cell-damaging effects than well-dis-
persed MWCNT as proven by various studies [22, 23]. In 
accordance with our results, various in vitro and in vivo 
studies revealed that acid-treated SWCNT and MWCNT 
with carboxyl groups caused a substantial degree of cyto-
toxicity and/or inflammatory response [22–25]. These 
strong toxic effects might be evoked by their high nega-
tive surface charge, which could lead to enhanced CNT–
cell-interactions [24]. In contrast and similar to our 
findings, MWCNT-OH were demonstrated to be less 
toxic than p-MWCNT or MWCNT-COOH [23]. Fur-
thermore, Muller et al. have shown that the presence of 
structural defects at the surface of MWCNT is associ-
ated with a diminished biocompatibility due to a higher 
reactivity of the defective MWCNT [26]. However, in 
Fig. 7 Release of AS-ODN following hybridization to CS-ODN 
adsorbed to MWCNT-OH at physiological conditions. The initial con-
centration of the Dy-557-labeled AS-ODN was 2 nmol/mgCNT and the 
released amount was determined by fluorescence measurements in 
the release solutions. The release studies were performed at 37 °C in 
0.9% NaCl solution, urine and different dilutions thereof
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the present study this should not be the case, because 
it has been shown by Raman spectroscopy that no fur-
ther defects have been introduced by the functionaliza-
tion process. Moreover, it was shown that EJ28 BCa cells 
could recover over the investigated time period follow-
ing incubation with pristine or modified MWCNT. In 
accordance, we could previously demonstrate that EJ28 
BCa cells treated with different p-MWCNT varying in 
diameter and length could recover over time [15].
Furthermore, a general uptake of all investigated 
MWCNT into cells was observed. Cellular internaliza-
tion into various cell types has already been shown for 
p-MWCNT, MWCNT-OH and MWCNT-COOH in 
our previous studies or by other groups [11, 16, 22, 23]. 
Here, the percentage of cells with internalized MWCNT 
ranged from 5 to 40% depending on the functional group 
of the MWCNT, whereupon MWCNT-OH had the high-
est and MWCNT-SH the lowest rates of internalization. 
The majority of MWCNT was located as agglomer-
ates inside vacuoles, which were hence enlarged due to 
the uptake of MWCNT. This indicates that MWCNT 
were incorporated into the cells as cellular vesicles by 
energy-dependent endocytosis, which is one possibility 
for the uptake of CNT [8, 27]. Another possibility is the 
passive uptake by nanopenetration leading to the loca-
tion of the MWCNT directly in the cytoplasm of cells 
[8, 27]. Of all investigated MWCNT within the present 
work, this could only be shown for MWCNT-OH. Ursini 
et  al. also demonstrated that MWCNT-OH were local-
ized freely in the cytoplasm and inside vacuoles, whereas 
MWCNT-COOH were only found inside vacuoles [23]. 
Furthermore, pristine and modified MWCNT were able 
to adhere to the urothelium of explanted mouse bladders. 
Similar to our previous findings with various p-MWCNT 
[15], all tested MWCNT types did not penetrate into 
deeper tissue layers and induced no visible signs of dam-
age on the surface of the mouse bladders. However, the 
amount of the covered area was rather low (2–7%) and 
thus it was not possible to clearly identify the superior-
ity of one modification over the other regarding their 
mucoadhesive potential. In a previous study by our 
group, different types of p-MWCNT led to similar per-
centages of covered urothelium from mouse bladders 
(5–10%) [15]. Apart from the present and our previous 
study, the mucoadhesive potential with regard to bladder 
treatment has so far only been investigated for nanopar-
ticles other than CNT using in vitro or ex vivo methods 
[28–35]. CNT could also be coated or functionalized 
with hydrophilic polymers such as gelatin or chitosan, 
which could further increase the dispersibility, biocom-
patibility and mucoadhesion [3, 36].
In addition to conventional drugs, MWCNT can 
also be loaded with therapeutic nucleic acids such as 
AS-ODN or siRNA [6–8]. AS-ODN, for instance, can be 
coupled to MWCNT via complementary carrier strands 
(CS-ODN), which have been either covalently or non-
covalently bound to MWCNT beforehand. In the present 
study, we could successfully attach CS-ODN by adsorp-
tion and covalent binding to the various MWCNT types. 
In order to evaluate the binding capacity and stability of 
CS-ODN to MWCNT, the amount of unbound fluores-
cent-labeled CS-ODN was determined in the supernatant 
of the binding reaction, the washing and release solu-
tions. This approach was necessary, because the fluores-
cence quenching effect of MWCNT hindered the direct 
quantification of bound CS-ODN. Adsorption of CS-
ODN to p-MWCNT, MWCNT-COOH and MWCNT-
NH2 as well as covalent coupling to MWCNT-NH2 and 
MWCNT-SH resulted in the best binding capacity and 
stability as indicated by low concentrations of CS-ODN 
in the supernatant, washing and releasing solutions.
However, it is difficult to distinguish between cova-
lent and non-covalent binding of CS-ODN to the CNT. 
The results suggest that the binding of CS-ODN to 
MWCNT was easier achieved by adsorption, particu-
larly for MWCNT-COOH. Covalent binding and adsorp-
tion are competing processes. Through its strong affinity 
and spontaneity the adsorption process is probably more 
dominant than the slower covalent reaction. This the-
sis was also confirmed, because p-MWCNT displayed 
the highest amount of bound CS-ODN. The presence of 
functional groups at the surface of MWCNT could pos-
sibly hinder the adsorption of CS-ODN to the function-
alized MWCNT. Responsible forces for an enhanced 
non-covalent adsorption of CS-ODN to MWCNT 
may be London dispersion forces and π–π-interactions 
between aromatic nucleobases and the aromatic gra-
phene rings of the MWCNT. Also, hydrogen bonds can 
be formed between nucleobases or the sugar-phosphate-
backbone and hydroxyl-groups of MWCNT-COOH 
and MWCNT-OH or amino-groups of MWCNT-NH2. 
Because the aromatic rings of the nucleobases and the 
MWCNT surface are hydrophobic, there are hydro-
phobic interactions between both. Furthermore, elec-
trostatic interactions could occur between negatively 
charged CS-ODN and the positively charged MWCNT-
SH and MWCNT-NH2 at neutral pH. p-MWCNT and 
MWCNT-OH are uncharged at neutral pH, whereas 
MWCNT-COOH are negatively charged, which could 
cause a repulsion with CS-ODN.
Subsequently, therapeutic AS-ODN could be hybrid-
ized to and reversibly released from the CS-ODN cou-
pled via both strategies to the functionalized MWCNT. 
At experimental conditions (80  °C, buffer), the release 
of AS-ODN from CS-ODN adsorbed to MWCNT was 
most effective from MWCNT-OH and MWCNT-NH2 
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followed by MWCNT-COOH and MWCNT-SH. The 
lowest release of AS-ODN was achieved for p-MWCNT 
despite the highest amount of adsorbed CS-ODN. The 
release of AS-ODN from CS-ODN covalently attached to 
MWCNT-COOH, MWCNT-NH2 or MWCNT-SH were 
similar and thus did not depend on the type of MWCNT 
functionalization. For all samples the specific hybridiza-
tion of AS-ODN to the CS-ODN at the MWCNT surface 
was indicated by the much lower release rate of NS-
ODN, which can only adsorb to the MWCNT. However, 
it was not possible to experimentally distinguish between 
hybridization of AS-ODN to CS-ODN and a potential 
adsorption of AS-ODN to the MWCNT surface. There-
fore, it might be possible that AS-ODN also adsorbed 
to free positions at the MWCNT surface in addition to 
hybridization to CS-ODN. By comparing the release of 
NS-ODN, which can only adsorb to the MWCNT, with 
the amount of released AS-ODN it was possible to esti-
mate the ratio of unspecific adsorption for AS-ODN. The 
highest hybridization rate of AS-ODN was observed for 
CS-ODN adsorbed to MWCNT-OH and MWCNT-NH2. 
This could in turn result in the superior release rate of 
AS-ODN from these MWCNT modifications, because 
hybridization is a reversible process and hybridized 
AS-ODN might be easier released than the additional 
adsorbed portion.
Moreover, we could exemplarily demonstrate that AS-
ODN could be released following hybridization to CS-
ODN adsorbed to MWCNT-OH at physiological settings 
(37  °C, urine). The release in urine and NaCl as well as 
mixtures thereof was carried out to investigate the clini-
cal applicability of the AS-ODN release from MWCNT. 
0.9% NaCl solution is normally used as clinical instil-
lation solution. The release of AS-ODN was lowest in 
0.9% NaCl, whereas with an increasing amount of urine 
the release of AS-ODN also increased. It is possible that 
the stability of the AS-ODN hybridization is higher in 
the NaCl solution, because there is a higher concentra-
tion of monovalent counterions, which shield the phos-
phate–phosphate repulsion inside the double helix. 
When the urea concentration increases, the electrostatic 
forces between the negatively charged DNA phosphate 
backbone and sodium ions are decreasing leading to an 
enhanced release of AS-ODN. Furthermore, there are 
hydrogen bonds preferentially formed between nucle-
obases and urea instead of complementary base pairing, 
which causes a destabilization of the double helix and a 
release of AS-ODN [37]. In summary, for a clinical appli-
cation it will be advantageous, when there is no release 
during instillation with NaCl. This will ensure that the 
release of AS-ODN first starts inside the bladder, when 
an increasing amount of urea facilitates the destabiliza-
tion of the AS-ODN/CS-ODN-bond.
To date, only a few groups have investigated CNT as 
delivery vectors for AS-ODN or ODN. Jia et  al. could 
efficiently transport AS-ODN against telomerase into 
cell nuclei by means of polyethylenimine-functionalized 
MWCNT-COOH, which led to a much higher cellular 
apoptosis than cell transfection with naked AS-ODN 
[13]. AS-ODN against c-myc conjugated to MWCNT-
NH2 modified with polyamidoamine dendrimers could 
mediate a substantial inhibition of cell growth and c-myc 
expression [14]. Furthermore, SWCNT-COOH served 
as efficient vector for the intracellular delivery of decoy 
ODN against NF-κB, which hence could significantly 
diminish the NF-κB-dependent gene expression [12]. 
In our previous study, AS-ODN against the angiogenic 
growth factor VEGF could be released after hybridiza-
tion to CS-ODN adsorbed onto MWCNT-OH at physi-
ological conditions (37  °C, buffer) at slightly basic pH 
values. MWCNT-OH could also mediate an uptake of 
AS-ODN into EJ28 BCa cells, which resulted in a mar-
ginal inhibition of cellular viability and VEGF expres-
sion [11]. However, other targets with more relevance to 
BCa such as survivin [38] and hTERT [39] could mediate 
more pronounced anti-proliferative effects upon inhibi-
tion through AS-ODN than VEGF. This should be inves-
tigated in future studies.
Conclusions
We could successfully functionalize p-MWCNT with 
hydrophilic moieties (MWCNT-OH, -COOH, -NH2, 
-SH), which led to an improved dispersibility and dis-
persion stability as well as to an enhanced biocom-
patibility for most of the modifications. All MWCNT 
were internalized by BCa cells and could adhere to 
the urothelium of explanted mouse bladders, although 
the amount of the covered urothelial area was rather 
low. AS-ODN could be hybridized to CS-ODN which 
were either adsorbed or covalently bound to pristine 
or functionalized MWCNT. However, the reversible 
release of AS-ODN at experimental conditions (80  °C, 
buffer) was most effective from CS-ODN attached to 
functionalized MWCNT, whereas it was the least effec-
tive from CS-ODN attached to p-MWCNT. Further-
more, we could exemplarily demonstrate that AS-ODN 
hybridized to MWCNT-OH-bound CS-ODN could 
also be released at physiological settings (37 °C, urine). 
Taken together, MWCNT functionalized with hydro-
philic moieties represent an interesting strategy for 
the intravesical treatment of BCa with therapeutic AS-
ODN. Nevertheless, the mucoadhesive properties of 
MWCNT-based delivery systems and thus their dwell 
time at the urothelium have to be improved further 
possibly via coating or functionalization with hydro-
philic polymers.
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